Clinical Trial Update: A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older [Phase 2]

View source ↗

Summary

A Phase 2 immunogenicity and safety trial update for Guangzhou Patronus Biotech's Recombinant Zoster Vaccine (CHO Cell), LYB004, in adults aged 40 and older, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Recombinant Zoster Vaccine (CHO Cell) LYB004 (recombinant zoster vaccine)

Snippet

Sponsor: Guangzhou Patronus Biotech Co., Ltd. | Conditions: Herpes Zoster (HZ), Shingles | Phase 2 | Status: ACTIVE_NOT_RECRUITING